ABT Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 12.79% compared to Abbott Laboratories's net margin of 14.45%. Abbott Laboratories's return on equity of 31.31% beat Boston Scientific's return on equity of 9.57%.

Abbott Laboratories has a consensus price target of $141.12, signalling upside risk potential of 6.12%. On the other hand Boston Scientific has an analysts' consensus of $117.14 which suggests that it could grow by 15.64%. Given that Boston Scientific has higher upside potential than Abbott Laboratories, analysts believe Boston Scientific is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.734, which suggesting that the stock is 26.647% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.681, suggesting its less volatile than the S&P 500 by 31.908%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.71%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $10.4B, which are larger than Boston Scientific quarterly revenues of $4.7B. Abbott Laboratories's net income of $1.3B is higher than Boston Scientific's net income of $674M. Notably, Abbott Laboratories's price-to-earnings ratio is 17.25x while Boston Scientific's PE ratio is 73.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.49x versus 8.59x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 12.79% compared to Abbott Laboratories's net margin of 30.99%. Abbott Laboratories's return on equity of 31.31% beat Intuitive Surgical's return on equity of 15.82%.

Abbott Laboratories has a consensus price target of $141.12, signalling upside risk potential of 6.12%. On the other hand Intuitive Surgical has an analysts' consensus of $575.49 which suggests that it could grow by 12.98%. Given that Intuitive Surgical has higher upside potential than Abbott Laboratories, analysts believe Intuitive Surgical is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.734, which suggesting that the stock is 26.647% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.875%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.71%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $10.4B, which are larger than Intuitive Surgical quarterly revenues of $2.3B. Abbott Laboratories's net income of $1.3B is higher than Intuitive Surgical's net income of $698.4M. Notably, Abbott Laboratories's price-to-earnings ratio is 17.25x while Intuitive Surgical's PE ratio is 74.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.49x versus 21.22x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 12.79% compared to Abbott Laboratories's net margin of 11.15%. Abbott Laboratories's return on equity of 31.31% beat Stryker's return on equity of 14.2%.

Abbott Laboratories has a consensus price target of $141.12, signalling upside risk potential of 6.12%. On the other hand Stryker has an analysts' consensus of $421.46 which suggests that it could grow by 12.22%. Given that Stryker has higher upside potential than Abbott Laboratories, analysts believe Stryker is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.734, which suggesting that the stock is 26.647% less volatile than S&P 500. In comparison Stryker has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.615%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.71%. Stryker offers a yield of 0.87% to investors and pays a quarterly dividend of $0.84 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $10.4B, which are larger than Stryker quarterly revenues of $5.9B. Abbott Laboratories's net income of $1.3B is higher than Stryker's net income of $654M. Notably, Abbott Laboratories's price-to-earnings ratio is 17.25x while Stryker's PE ratio is 50.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.49x versus 6.24x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of 12.79% compared to Abbott Laboratories's net margin of -55.69%. Abbott Laboratories's return on equity of 31.31% beat Tandem Diabetes Care's return on equity of -81.14%.

Abbott Laboratories has a consensus price target of $141.12, signalling upside risk potential of 6.12%. On the other hand Tandem Diabetes Care has an analysts' consensus of $32.70 which suggests that it could grow by 61.72%. Given that Tandem Diabetes Care has higher upside potential than Abbott Laboratories, analysts believe Tandem Diabetes Care is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.734, which suggesting that the stock is 26.647% less volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.517, suggesting its more volatile than the S&P 500 by 51.705%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.71%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $10.4B, which are larger than Tandem Diabetes Care quarterly revenues of $234.4M. Abbott Laboratories's net income of $1.3B is higher than Tandem Diabetes Care's net income of -$130.6M. Notably, Abbott Laboratories's price-to-earnings ratio is 17.25x while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.49x versus 1.35x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.